PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontphysiolLink to Publisher's site
 
Front Physiol. 2017; 8: 127.
Published online 2017 March 2. doi:  10.3389/fphys.2017.00127
PMCID: PMC5332388

Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disorder, caused by a polyglutamine expansion in the huntingtin protein (HTT). HD has a peripheral component to its pathology: skeletal muscles are severely affected, leading to atrophy, and malfunction in both pre-clinical and clinical settings. We previously used two symptomatic HD mouse models to demonstrate the impairment of the contractile characteristics of the hind limb muscles, which was accompanied by a significant loss of function of motor units. The mice displayed a significant reduction in muscle force, likely because of deteriorations in energy metabolism, decreased oxidation, and altered purine metabolism. There is growing evidence suggesting that HD-related skeletal muscle malfunction might be partially or completely independent of CNS degeneration. The pathology might arise from mutant HTT within muscle (loss or gain of function). Hence, it is vital to identify novel peripheral biomarkers that will reflect HD skeletal muscle atrophy. These will be important for upcoming clinical trials that may target HD peripherally. In order to identify potential biomarkers that might reflect muscle metabolic changes, we used qPCR to validate key gene transcripts in different skeletal muscle types. Consequently, we report a number of transcript alterations that are linked to HD muscle pathology.

Keywords: Huntington's disease, skeletal muscle atrophy, purine metabolism, transcriptional deregulation, biomarkers, mouse models

Introduction

Skeletal muscle loss and dysfunction are often associated with aging but are also found in many chronic diseases with diverse etiologies (Vinciguerra et al., 2010). The list includes Huntington's disease (HD), which is a monogenic neurodegenerative disorder caused by a CAG-repeat expansion within the huntingtin gene (HTT). The expansion mutation is found in Exon-1 and translates into a polyglutamine stretch (polyQ) in HTT protein, which alters function (for a recent review see Zielonka et al., 2015). To date, the best functional description of HTT is as a “scaffolding protein.” This is because HTT has many interaction partners and these are involved in a wide variety of cellular processes, including gene transcription, intracellular signaling, trafficking, endocytosis, and metabolism (Harjes and Wanker, 2003), hence one might describe HD as a multi-system disorder (Mielcarek, 2015).

In humans, HD is characterized by motor dysfunction, cognitive decline, and a progressive dementia, with the first symptoms typically occurring in midlife (for review see Zielonka et al., 2015). Although HD is still being described as a neurological disorder, there is incontrovertible and growing evidence that peripheral pathology participates in disease progression (Mielcarek, 2015). This is in line with the fact that HTT is normally expressed at high levels in a wide variety of mammalian tissues (Li et al., 1993). Furthermore, pathological high molecular weight HTT aggregates have been identified in many non-central nervous system tissues including skeletal muscle (Moffitt et al., 2009), although interestingly not in hearts (Mielcarek et al., 2014a). Aggregation of mutant HTT is widely-believed to be one of the most important HD molecular pathology signatures and can be detected at an early pre-symptomatic stage in both pre-clinical and clinical HD settings (Davies et al., 1997). HD-related skeletal muscle malfunction has been widely described in both these settings (reviewed in Zielonka et al., 2014a; Mielcarek and Isalan, 2015).

Skeletal muscle constitutes up to 40% of body mass and, in healthy conditions, its function is orchestrated by a balanced network of intrinsic hypertrophic and atrophic signals that maintain metabolic homeostasis (Arinze, 2005; Ehrenborg and Krook, 2009). Any imbalance in these signals may lead to the impairment of muscle regeneration and, consequently, may cause a detrimental dysfunction of skeletal muscle, as has been observed in many chronic diseases (Bassel-Duby and Olson, 2006; Brooks and Myburgh, 2014). We have recently described physiological and functional changes in the skeletal muscles of two well-established HD mouse models, namely R6/2 and HdhQ150 (Mielcarek et al., 2015). We found that these symptomatic HD mouse models had substantial alterations in energy equilibria in various skeletal muscles. This was accompanied by decreased levels of the phosphocreatine/creatine ratios, as well as lower ADP and AMP levels. Moreover, the total pools of the adenine nucleotides were also consistently depleted. Finally, our previous analysis revealed that the EDL muscle showed a slower glycolytic flux from exogenous glucose, as well as less oxidation of glucose (Mielcarek et al., 2015).

In order to underpin our understanding of these metabolic changes, we performed the current transcriptional signature study. For comparability, we employed the same HD mouse model (R6/2) in which we previously described muscle energy imbalances with alterations of purine nucleotides. Since we previously showed that purine metabolism is significantly altered in pre-clinical HD settings (Mielcarek et al., 2015), our current study exclusively focused on the key transcriptional elements of this process as these might serve as important molecular biomarkers for up-coming pre-clinical and clinical studies in HD.

Finally, it should be noted that HD was initially recognized as neurological disorder; although peripheral pathology was noticed, it was generally believed that the changes in peripheral organs were a consequence of CNS degeneration. As a result, over the past decades, researchers concentrated on identifying HD biomarkers that are exclusively attributed to CNS degeneration. However, a number of recently published studies have indicated that skeletal muscle atrophy might be driven by intrinsic mutant HTT functions in muscle (for review Zielonka et al., 2015). Moreover, HD has started to be recognized as a multi-system disorder (Mielcarek, 2015). Hence, there is an urgent need to identify biomarkers that will reflect peripheral pathological changes including those related to HD-skeletal muscle atrophy.

Materials and methods

Mouse maintenance and genotyping

The R6/2 HD mouse line was bred and genotyped as previously described (Mielcarek et al., 2015; Agustín-Pavón et al., 2016). All experimental procedures were conducted under a project license from the Home Office, UK and approved by the Animal Welfare and Ethical Review Body of Imperial College London. Experimental groups included the R6/2 mouse model at 12 weeks of age (n = 6) and their C57BL/6J littermates (n = 6). All animals had unlimited access to water and breeding chow (Special Diet Services, Witham, UK), and housing conditions and environmental enrichment were as described previously (Mielcarek et al., 2015; Agustín-Pavón et al., 2016).

RNA extraction and taqman real-time PCR expression analysis

Total RNA from skeletal muscles was extracted with the mini-RNA kit (Qiagen, UK), according to the manufacturer's instructions. The reverse transcription reaction was performed using MMLV superscript reverse transcriptase (Invitrogen, USA) and random hexamers (Sigma, USA), as described in an earlier study (Mielcarek et al., 2011). All Taqman qPCR reactions were performed with a LightCycler® 480 Instrument (Roche), as described previously (Agustín-Pavón et al., 2016). Following Taq-man assays from Thermo Fisher Scientific were used in this study Adsl (Mm_00507759_m1); Adssl1 (Mm_00475814_m1); Gart (Mm_00599836_m1); Ppat (Mm_00549096_m1); Aprt (Mm_04207857_g1); Ak1 (Mm_00445475_m1); Gmpr (Mm_00499393_m1); Impdh2 (Mm_00496156_m1); Ada (Mm_00545720_m1); Adk (Mm_00612772_m1); Nt5e (Mm_00501910_m1); Ampd3 (Mm_00477495_m1); Entpd2 (Mm_00515450_m1); Pnp (Mm_00840006_m1); Xdh (Mm_00442110_m1); Prkaa1 (Mm_01296700_m1); Pdk4 (Mm_01166879_m1); Hk2 (Mm_00443385_m1). mRNA copy number was determined in triplicate for each RNA sample by comparison with the geometric mean of three endogenous housekeeping genes (Primer Design, UK), as described (Mielcarek et al., 2011). Stable housekeeping genes for qPCR profiling of various skeletal muscles for HD mouse models were determined using the Primer Design geNormHousekeeping Gene Selection Mouse Kit with PerfectProbesoftware.

Statistical analysis

Values were presented as mean ± SEM. Statistical analysis was performed using paired Student t-tests (Excel) or One-Way Anova SPSS (IBM). A p-value of 0.05 was considered as a significant difference.

Results

In order to establish the transcriptional signature related to the pathology observed in HD skeletal muscle, we employed the R6/2 transgenic mouse model of HD, representing the fully symptomatic stage of a rapid-onset form of the disease. Since the characteristic energy imbalance was previously detected in all muscle types, we performed a detailed profiling of transcriptional changes related to purine metabolism and energy balance within different muscles. We focused on Extensor Digitus Longum (EDL), Soleus (Sol), Tibialis Anterior (TA) and Gastrocnemius, and Plantaris complex (G/P) because these are composed from metabolically-different muscle fibers. Typically, hindlimb muscles can be divided into two groups (fast and slow) based on the composition of fibers, containing up to four myosin isoforms. Type I fibers are also known as slow twitch fibers and they produce ATP through an aerobic metabolic cycle. Type IIa fibers are also known as intermediate fast oxidative fibers and they produce ATP through both aerobic and anaerobic metabolic pathways. Type IIb fibers are known as fast glycolytic fibers and they produce ATP through an anaerobic metabolic cycle (Schiaffino and Reggiani, 2011). Figure Figure1A1A summarizes the hindlimb muscle classification used in this study, based on a previously published study in the C57BL6J mouse strain (Augusto et al., 2004).

Figure 1
(A) Summary of composition of fiber types in the hindlimb skeletal muscles used in this study. (B) Identification of reference genes for qPCR from Soleus RNA from the R6/2 mouse model. GeNorm analysis was used to identify optimal reference genes. Raw ...

Since HD causes large amount of transcriptional deregulation, we performed a systematic study to identify suitable reference genes for use in the expression analysis of different skeletal muscle types. We previously established a number of housekeeping genes that are stable across the different muscle types used in this study, summarized in Table Table11 (Mielcarek et al., 2015). We used the geNorm™ Housekeeping Gene Selection Mouse Kit, and associated software, to identify the three most stably-expressed genes in Soleus muscles from R6/2 (Figure (Figure1B).1B). This approach was necessary for our relative quantification method; this uses the geometric mean of three selected reference genes for normalization, to accurately determine gene expression levels in WT and R6/2 skeletal muscle tissue, summarized in Table Table11.

Table 1
Summary of housekeeping genes specific for each muscle type in the R6/2 HD mouse model used in this study.

Since we showed previously that purine metabolism is altered in HD skeletal muscles (Mielcarek et al., 2015), we next studied the transcriptional signature of genes involved in de novo purine synthesis. These were examined in different muscles in the R6/2 HD mouse model, using comparisons to control WT littermates.

First, we found that the transcript levels of two genes involved in the purine nucleotide cycle (PNC) were significantly down-regulated. Adenylosuccinate lyase (Adsl, Figure Figure2A)2A) and Adenylosuccinate lyase 1 (Adlssl1, Figure Figure2B)2B) were reduced by ~40–80% in each type of skeletal muscle.

Figure 2
Transcriptional remodeling of genes involved in de novo purine synthesis and salvage pathway. Transcripts of genes involved in de novo purine biosynthesis. (A) Adsl, Adenylosuccinate lyase; (B) Adssl1, Adenylosuccinate lyase 1; (C) Gart, Phosphoribosylglycinamide ...

When examining the mRNA levels of enzymes involved in purine synthesis, we found that Phosphoribosylglycinamide formyltransferase (Gart) was significantly up-regulated (up to 2-fold) in each type of skeletal muscle (Figure (Figure2C).2C). In contrast, Adenine phosphoribosyltransferase (Aprt) and Amidophosphoribosyltransferase (Ppat) mRNA remained unchanged (Figures 2D,E).

We also examined the transcriptional changes of genes involved in the conversion of purine nucleotides. We found that mRNA levels of Adenylate kinase 1 (Ak1; an enzyme that is involved in the catalysis of the terminal phosphate group between ATP and AMP) were significantly down-regulated in each type of skeletal muscle examined (Figure (Figure3A).3A). Conversely, the transcript levels of Inosine monophosphate dehydrogenase 2 (Impdh2), which catalyzes the conversion of IMP (Inosine 5′-phosphate) to XMP (Xanthosine 5′-phosphate), were significantly up-regulated, by up to 2-fold (Figure (Figure3C).3C). The transcript levels of Guanosine monophosphate reductase (Gmpr; maintains the intracellular balance of adenine and guanine nucleotides) remained unchanged (Figure (Figure3B3B).

Figure 3
Transcriptional alteration of genes engaged in conversion of adenine nucleotides. Transcripts of (A) Ak1, Adenylate kinase 1; (B) Gmpr, Guanosine monophosphate reductase; and (C) Impdh2, inosine monophosphate dehydrogenase 2; were assessed in different ...

Subsequently, we verified the transcriptional changes of selected genes that are believed to be involved in adenosine metabolism. The mRNA levels of Ada (Adenosine deaminase; Figure Figure4A),4A), Adk (Adenosine kinase; Figure Figure4B)4B) and Nt5e (Ecto-5′-nucelotidase; Figure Figure4C)4C) remained unchanged under all conditions.

Figure 4
Unchanged transcriptional levels of genes involved in in adenosine metabolism. Transcripts of (A) Ada, Adenosine deaminase; (B) Adk, Adenosine kinase; and (C) Nt5e, Ecto-5′-nucleotidase; were assessed in different types of skeletal muscle: EDL, ...

We next assessed the transcriptional signature of genes involved in purine metabolism and their degradation. There was a significant up-regulation of the Ampd3 (Adenosine monophosphate deaminase 3) specifically in the fast-type muscles like EDL (Figure (Figure5A).5A). In fact, the effect was large (up to 9-fold), which is interesting given that Ampd3 is a marker of skeletal muscle denervation (Fortuin et al., 1996). In addition, we observed a robust Ampd3 mRNA up-regulation in other muscle types like soleus (up to 5-fold), TA (up to 6-fold), and G/P (up to 2.5-fold).

Figure 5
Transcriptional remodeling of genes involved in purine metabolism and their degradation. Transcript levels of (A) Ampd3, Adenosine deaminase 3; (B) Entpd2, Ectonucleoside triphosphate diphosphohydrolase 2; (C) Pnp, Purine nucleoside phosphorylase; (D) ...

There was a significant down-regulation across tested conditions of Entpd2 (Ectonucleoside triphosphate diphosphohydrolase 2; regulates ATP hydrolysis), specifically in fast-type skeletal muscles, such as EDL (Figure (Figure5B).5B). Contrastingly, the mRNA levels of Pnp (Purine nucleoside phosphorylase) were significantly and uniformly up-regulated across each muscle examined (Figure (Figure5C5C).

We further validated the expression levels of mRNAs coding for enzymes involved in purine degradation pathways (Yang et al., 2008; Walker et al., 2011). We found that Xdh (Xanthine dehydrogenase) transcript levels were significantly up-regulated, uniformly across all conditions (Figure (Figure5D5D).

Finally, we assessed the expression levels of two genes involved in energy metabolism. Prkaa1 (5-AMP-activated protein kinase catalytic subunit alpha-1) mRNA levels were significantly up-regulated up to 3-fold, in both fast- and slow-type skeletal muscle (Figure (Figure6A).6A). Similarly, Pdk4 (Pyruvate dehydrogenase, kinase isozyme 4) transcript levels were found to be up-regulated up to 6-fold in fast-type muscle (EDL; Figure Figure6B).6B). The transcript levels of Hk2 (Hexokinase 2) were significantly down-regulated, particularly in the fast-type muscles like EDL (Figure (Figure6C).6C). Thus, one may conclude that there was a significant deregulation of both these energy metabolism genes, whose function we previously reported to be deregulated in HD mouse models (Mielcarek et al., 2015). Overall, the changes in transcript levels in different muscles in the R6/2 HD mouse model are summarized in Figure Figure77.

Figure 6
Transcriptional alteration of genes involved in energy homeostasis. Transcripts of genes involved in (A) Prkaa1, 5-AMP-activated protein kinase catalytic subunit alpha-1 and (B) Pdk4, Pyruvate dehydrogenase, kinase isozyme 4; (C) Hk2, Hexokinase ...
Figure 7
Summary of significantly deregulated transcripts in HD skeletal muscles that might alter purine homeostasis, leading to an energy imbalance. Adsl, Adenylosuccinate lyase; Adssl1, Adenylosuccinate lyase 1; Gart, Phosphoribosylglycinamide formyltransferase ...

Discussion

HD is an autosomal dominant, progressive, neurodegenerative disorder for which there are currently only symptomatic treatments, reviewed in Zielonka et al. (2015). There is a clear need to develop disease modifying therapies and the progress of these can be informed by new insights into the underlying molecular pathologies. For instance, it is becoming more-and-more apparent that HD can be described as mitochondriopathy: multiple studies have described mitochondrial defects, both in vitro and in vivo, that might play a central role in HD CNS degeneration (for review see Damiano et al., 2010). Furthermore, it is emerging that HD has a peripheral component contributing to its pathology, including skeletal muscle atrophy (Zielonka et al., 2014a) and heart failure (Zielonka et al., 2014b). In fact, HD-related cardiomyopathy is characterized by brady- and tachyar-rhythmias, variations in heart rates and cardiac remodeling (Mielcarek et al., 2014a), and these are in line with recently published clinical data (Stephen et al., 2015). Consequently, it has been shown that these cardiac pathologies might be caused by significant alterations in mitochondrial structure, including the loss of mitochondrial elongated shapes and diffused mitochondrial densities (Mihm et al., 2007; Kiriazis et al., 2012). Supporting this view of altered mitochondrial energy metabolism, we observed an increased level of purine catabolites in the heart mass of HD mouse models (Toczek et al., 2016a,b). In addition, reactive oxygen species (ROS) play an important role in mitochondrial dysfunction, especially in skeletal muscle atrophy (Zuo et al., 2015; Zuo and Pannell, 2015) and heart failure (He and Zuo, 2015). Similarly, ROS overproduction has been linked to many neurodegenerative diseases (Manoharan et al., 2016), including HD (Ayala-Peña, 2013). In fact, it has been shown that mutant HTT aggregation directly leads to increased ROS production in vitro (Hands et al., 2011).

A mitochondrial dysfunction is also present in HD skeletal muscle. For example, HD subjects develop a deficit in mitochondrial oxidative metabolism in skeletal muscles (Saft et al., 2005). This was shown in muscle cell cultures that exhibited abnormalities in mitochondrial membrane potential and cytochrome 3 release (Ciammola et al., 2006). Additionally, our recently published study in HD pre-clinical settings clearly identified an energy deficit and altered metabolism of purine nucleotides, spanning both fast and slow types of skeletal muscle (Mielcarek et al., 2015). This mechanism underpins the progressive impairment of the contractile characteristics of skeletal muscles in HD. In fact, we previously reported that the pool of ATP, ADP, and NAD+ was depleted in fast (EDL) and slow (Soleus) types of skeletal muscle, in R6/2 and HdhQ150 mouse models (Mielcarek et al., 2015). Hence, the aim of this study was to identify a transcriptional signature that is linked to the observed imbalance in purine metabolism and energy production, in order to identify a set of novel biomarkers for HD-related pathology.

A key feature of our study is that we performed our analysis on different types of skeletal muscle, chosen for their contrasting fiber compositions. Therefore, we carried out our transcriptional analysis on EDL (fast-type muscle), Soleus (slow-type muscle), and TA or G/P (mixed fiber compositions). It should be emphasized that skeletal muscle atrophy in HD affects both types of muscles (slow and fast; Sathasivam et al., 1999; Mielcarek et al., 2015). However, the process of atrophy is greater in type II fibers (fast), relative to type I (slow; Ribchester et al., 2004), which in turn may result in a fast-to-slow twitch conversion.

Muscle atrophy can also alter gene expression and Ampd3 is believed to be a marker of muscle disuse and muscle denervation (Fortuin et al., 1996). Interestingly, we found a robust up-regulation of Ampd3 transcript levels (up to 9-fold). This is in line with our previous data, indicating that HD muscles are becoming denervated due to loss of motor units function or their inactivity (Mielcarek et al., 2015).

Moreover, we found changes in gene expression that tie in to our previous observations of altered metabolism in HD skeletal muscle (Mielcarek et al., 2015). For example, there was a significant up-regulation (up to 3-fold) of genes such as Pnp and Xdm, which are linked directly to purine metabolism. We also noticed a significant up-regulation of transcripts that are involved in energy homeostasis, including Prkaa1 (up to 4-fold) and Pdk4 (up to 6-fold; for a review see Ehrenborg and Krook, 2009). On the other hand, we found a number of gene transcripts to be down-regulated and these are linked to de novo purine synthesis, like Adsl and Adssl1, followed by Entpd2 and Hk2 (both involved in purine metabolism).

In summary, we report the first transcriptional signature that represents changes in energy homeostasis and an altered purine metabolism in the skeletal muscles of an HD mouse model (Figure (Figure7).7). We believe that the genes used here might provide a useful set of HD biomarkers, both for tracking disease progression and for developing therapies. In fact, there is a growing interest in including skeletal muscle malfunction as a therapeutic target to delay disease progression in HD (Mielcarek et al., 2014b; Zielonka et al., 2014a; Mielcarek, 2015). For example, it was recently shown that reversing skeletal muscle malfunction, by blocking the myostatin pathway, extended the lifespan of the R6/2 mouse model (Mielcarek et al., 2014b). Additionally, HD skeletal muscle shows a denervation-like phenotype, which might be linked to the deregulated HDAC4-myogenin axis (Mielcarek et al., 2015), and HDAC4 is a valid therapeutic target in HD (Mielcarek et al., 2011, 2013).

Ultimately, lowering levels of mutant Huntingtin in HD settings is the most widely accepted therapeutic strategy and here it would be useful to have a set of biomarkers for both central and peripheral (e.g., skeletal muscle) pathology. In this context, we recently published an approach based on artificial zinc finger transcription repressors, targeted to mutant HTT (Garriga-Canut et al., 2012; Agustín-Pavón et al., 2016). We showed that a single AAV delivery treatment can repress the mutant gene in mouse brains for up to 6 months (Agustín-Pavón et al., 2016) and the treatment has the potential to be extended to HD muscle therapy. Hence, our panel of newly identified HD-associated transcripts, which are related to purine metabolism and energy imbalance, might serve as a biomarker platform in such pre-clinical settings. Finally, since HD-related skeletal muscle atrophy shares many molecular and physiological mechanisms with muscle cachexia in cancer mouse models (Mielcarek and Isalan, 2015), it is likely that our set of transcriptional biomarkers may have even wider applications in these settings.

Author contributions

Conceived and designed the experiments: MM, RS, MI. Performed the experiments: MM. Analyzed the data: MM, RS, MI. Wrote the manuscript: MM, MI.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by the National Science Centre of Poland (2011/01/B/NZ4/03719); the Foundation for Polish Science (TEAM/2011-8/7); funding from European Research Council grant H2020—ERC-2014-PoC 641232—Fingers4Cure; and an Imperial/ICR/NIHR BRC/NHS Confidence in Concept (iCiC) grant. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • Agustín-Pavón C., Mielcarek M., Garriga-Canut M., Isalan M. (2016). Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol. Neurodegener. 11, 64. 10.1186/s13024-016-0128-x [PMC free article] [PubMed] [Cross Ref]
  • Arinze I. J. (2005). Facilitating understanding of the purine nucleotide cycle and the one-carbon pool: Part I: the purine nucleotide cycle. Biochem. Mol. Biol. Educ. 33, 165–168. 10.1002/bmb.2005.494033032469 [PubMed] [Cross Ref]
  • Augusto V., Padovani C. R., Campos G. E. R. (2004). Skeletal muscle fiber types in C57BL6J mice. Braz. J. Morphol. Sci. 21, 89–94.
  • Ayala-Peña S. (2013). Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. Free Radic. Biol. Med. 62, 102–110. 10.1016/j.freeradbiomed.2013.04.017 [PMC free article] [PubMed] [Cross Ref]
  • Bassel-Duby R., Olson E. N. (2006). Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75, 19–37. 10.1146/annurev.biochem.75.103004.142622 [PubMed] [Cross Ref]
  • Brooks N. E., Myburgh K. H. (2014). Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways. Front. Physiol. 5:99. 10.3389/fphys.2014.00099 [PMC free article] [PubMed] [Cross Ref]
  • Ciammola A., Sassone J., Alberti L., Meola G., Mancinelli E., Russo M. A., et al. . (2006). Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ. 13, 2068–2078. 10.1038/sj.cdd.4401967 [PubMed] [Cross Ref]
  • Damiano M., Galvan L., Déglon N., Brouillet E. (2010). Mitochondria in Huntington's disease. Biochim. Biophys. Acta 1802, 52–61. 10.1016/j.bbadis.2009.07.012 [PubMed] [Cross Ref]
  • Davies S. W., Turmaine M., Cozens B. A., Difiglia M., Sharp A. H., Ross C. A., et al. . (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537–548. 10.1016/S0092-8674(00)80513-9 [PubMed] [Cross Ref]
  • Ehrenborg E., Krook A. (2009). Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol. Rev. 61, 373–393. 10.1124/pr.109.001560 [PubMed] [Cross Ref]
  • Fortuin F. D., Morisaki T., Holmes E. W. (1996). Subunit composition of AMPD varies in response to changes in AMPD1 and AMPD3 gene expression in skeletal muscle. Proc. Assoc. Am. Physicians 108, 329–333. [PubMed]
  • Garriga-Canut M., Agustín-Pavón C., Herrmann F., Sánchez A., Dierssen M., Fillat C., et al. . (2012). Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc. Natl. Acad. Sci. U.S.A. 109, E3136–E3145. 10.1073/pnas.1206506109 [PubMed] [Cross Ref]
  • Hands S., Sajjad M. U., Newton M. J., Wyttenbach A. (2011). In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J. Biol. Chem. 286, 44512–44520. 10.1074/jbc.M111.307587 [PMC free article] [PubMed] [Cross Ref]
  • Harjes P., Wanker E. E. (2003). The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28, 425–433. 10.1016/S0968-0004(03)00168-3 [PubMed] [Cross Ref]
  • He F., Zuo L. (2015). Redox roles of reactive oxygen species in cardiovascular diseases. Int. J. Mol. Sci. 16, 27770–27780. 10.3390/ijms161126059 [PMC free article] [PubMed] [Cross Ref]
  • Kiriazis H., Jennings N. L., Davern P., Lambert G., Su Y., Pang T., et al. . (2012). Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease. J. Physiol. 590, 5845–5860. 10.1113/jphysiol.2012.238113 [PubMed] [Cross Ref]
  • Li S. H., Schilling G., Young W. S., III, Li X. J., Margolis R. L., Stine O. C., et al. . (1993). Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11, 985–993. 10.1016/0896-6273(93)90127-D [PubMed] [Cross Ref]
  • Manoharan S., Guillemin G. J., Abiramasundari R. S., Essa M. M., Akbar M., Akbar M. D. (2016). The role of reactive oxygen species in the pathogenesis of Alzheimer's disease, parkinson's disease, and huntington's disease: a mini review. Oxid. Med. Cell. Longev. 2016:8590578. 10.1155/2016/8590578 [PMC free article] [PubMed] [Cross Ref]
  • Mielcarek M. (2015). Huntington's disease is a multi-system disorder. Rare Dis. 3:e1058464. 10.1080/21675511.2015.1058464 [PMC free article] [PubMed] [Cross Ref]
  • Mielcarek M., Benn C. L., Franklin S. A., Smith D. L., Woodman B., Marks P. A., et al. . (2011). SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS ONE 6:e27746. 10.1371/journal.pone.0027746 [PMC free article] [PubMed] [Cross Ref]
  • Mielcarek M., Inuabasi L., Bondulich M. K., Muller T., Osborne G. F., Franklin S. A., et al. . (2014a). Dysfunction of the CNS-heart axis in mouse models of Huntington's disease. PLoS Genet. 10:e1004550. 10.1371/journal.pgen.1004550 [PMC free article] [PubMed] [Cross Ref]
  • Mielcarek M., Isalan M. (2015). A shared mechanism of muscle wasting in cancer and Huntington's disease. Clin. Transl. Med. 4, 34. 10.1186/s40169-015-0076-z [PMC free article] [PubMed] [Cross Ref]
  • Mielcarek M., Landles C., Weiss A., Bradaia A., Seredenina T., Inuabasi L., et al. . (2013). HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 11:e1001717. 10.1371/journal.pbio.1001717 [PMC free article] [PubMed] [Cross Ref]
  • Mielcarek M., Rattray I., Osborne G. F., Jolinon N., Dick J. R. T., Bondulich M. K., et al. (2014b). Myostatin inhibition as a novel approach to targeting muscle pathology in HD. J. Neurol. Neurosurg. Psychiatr. 85, A97 10.1136/jnnp-2014-309032.281 [Cross Ref]
  • Mielcarek M., Toczek M., Smeets C. J., Franklin S. A., Bondulich M. K., Jolinon N., et al. . (2015). HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. PLoS Genet. 11:e1005021. 10.1371/journal.pgen.1005021 [PMC free article] [PubMed] [Cross Ref]
  • Mihm M. J., Amann D. M., Schanbacher B. L., Altschuld R. A., Bauer J. A., Hoyt K. R. (2007). Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 25, 297–308. 10.1016/j.nbd.2006.09.016 [PMC free article] [PubMed] [Cross Ref]
  • Moffitt H., McPhail G. D., Woodman B., Hobbs C., Bates G. P. (2009). Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS ONE 4:e8025. 10.1371/journal.pone.0008025 [PMC free article] [PubMed] [Cross Ref]
  • Ribchester R. R., Thomson D., Wood N. I., Hinks T., Gillingwater T. H., Wishart T. M., et al. . (2004). Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 20, 3092–3114. 10.1111/j.1460-9568.2004.03783.x [PubMed] [Cross Ref]
  • Saft C., Zange J., Andrich J., Müller K., Lindenberg K., Landwehrmeyer B., et al. . (2005). Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20, 674–679. 10.1002/mds.20373 [PubMed] [Cross Ref]
  • Sathasivam K., Hobbs C., Turmaine M., Mangiarini L., Mahal A., Bertaux F., et al. . (1999). Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 8, 813–822. 10.1093/hmg/8.5.813 [PubMed] [Cross Ref]
  • Schiaffino S., Reggiani C. (2011). Fiber types in mammalian skeletal muscles. Physiol. Rev. 91, 1447–1531. 10.1152/physrev.00031.2010 [PubMed] [Cross Ref]
  • Stephen C., Hersch S., Rosas H. (2015). Huntington's disease and the heart: electrocardiogram abnormalities suggest cardiac involvement. Neurology 84 (Supp. P5.294).
  • Toczek M., Kutryb-Zajac B., Zukowska P., Slominska E., Isalan M., Mielcarek M., et al. . (2016a). Changes in cardiac nucleotide metabolism in Huntington's disease. Nucleosides Nucleotides Nucleic Acids 35, 707–712. 10.1080/15257770.2016.1154969 [PubMed] [Cross Ref]
  • Toczek M., Zielonka D., Zukowska P., Marcinkowski J. T., Slominska E., Isalan M., et al. . (2016b). An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy. Biochim. Biophys. Acta 1862, 2147–2157. 10.1016/j.bbadis.2016.08.019 [PubMed] [Cross Ref]
  • Vinciguerra M., Musaro A., Rosenthal N. (2010). Regulation of muscle atrophy in aging and disease. Adv. Exp. Med. Biol. 694, 211–233. 10.1007/978-1-4419-7002-2_15 [PubMed] [Cross Ref]
  • Walker P. L., Corrigan A., Arenas M., Escuredo E., Fairbanks L., Marinaki A. (2011). Purine nucleoside phosphorylase deficiency: a mutation update. Nucleosides Nucleotides Nucleic Acids 30, 1243–1247. 10.1080/15257770.2011.630852 [PubMed] [Cross Ref]
  • Yang J., Kamide K., Kokubo Y., Takiuchi S., Horio T., Matayoshi T., et al. . (2008). Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens. Res. 31, 931–940. 10.1291/hypres.31.931 [PubMed] [Cross Ref]
  • Zielonka D., Mielcarek M., Landwehrmeyer G. B. (2015). Update on Huntington's disease: advances in care and emerging therapeutic options. Parkinsonism Relat. Disord. 21, 169–178. 10.1016/j.parkreldis.2014.12.013 [PubMed] [Cross Ref]
  • Zielonka D., Piotrowska I., Marcinkowski J. T., Mielcarek M. (2014a). Skeletal muscle pathology in Huntington's disease. Front. Physiol. 5:380. 10.3389/fphys.2014.00380 [PMC free article] [PubMed] [Cross Ref]
  • Zielonka D., Piotrowska I., Mielcarek M. (2014b). Cardiac dysfunction in Huntington's disease. Exp. Clin. Cardiol. 20, 2547–2554.
  • Zuo L., Best T. M., Roberts W. J., Diaz P. T., Wagner P. D. (2015). Characterization of reactive oxygen species in diaphragm. Acta Physiol. 213, 700–710. 10.1111/apha.12410 [PubMed] [Cross Ref]
  • Zuo L., Pannell B. K. (2015). Redox characterization of functioning skeletal muscle. Front. Physiol. 6:338. 10.3389/fphys.2015.00338 [PMC free article] [PubMed] [Cross Ref]

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA